Cord Blood Banking Market to Hit $49.8B

The market is split between private banks, which store cord blood for a family's exclusive use, and public banks, which accept donations for anyone in need. Private banking involves initial fees up to $2,350 and annual storage costs around $175, while public donation is free for parents. Globally, there are approximately 4.3 million units stored in private banks, though this represents a small fraction of total births. In the U.S., about 3% of parents bank their newborn's cord blood. Key industry players include Cord Blood Registry (CBR) Systems, Cryo-Cell International, and ViaCord. Cord blood stem cells are currently FDA-approved to treat over 80 diseases, including various cancers, blood disorders like sickle cell anemia, and immune deficiencies. Historically, a key limitation has been the low number of stem cells in a single cord blood unit, often insufficient for treating adult patients. A major breakthrough addressing this limitation came in April 2023 with the FDA approval of Omisirge (omidubicel). It is the first expanded cord blood product, utilizing a technology that can significantly multiply the number of stem cells, making transplants more effective for adults. Public banking faces significant challenges, including financial sustainability and resource scarcity. Fewer than 200 U.S. hospitals participate in public collection programs, and it's estimated that nearly 70% of donations are discarded for not meeting strict processing and storage requirements. Finding a suitable match from a public bank can be difficult, particularly for patients of mixed or minority ethnicities. While Caucasians have a 70% chance of finding a match, the probability for other ethnicities can be as low as 10%.